
What is claimed is:


1. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 10.55, 13.61 and 19.84° 2θ.


2. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.80, 17.29 and 21.74° 2θ.


3. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.83, 17.26 and 21.86° 2θ.


4. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 10.37, 13.41 and 19.52° 2θ.


5. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.92, 17.29 and 21.81° 2θ.


6. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 18.53, 20.85 and 21.10° 2θ.


7. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.51, 17.90 and 21.28° 2θ.


8. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.74, 17.22 and 21.76° 2θ.


9. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 7.94, 16.00 and 18.27° 2θ.

10. An amorphous solid comprising Compound 1, or a tautomer thereof:




1.

11. A method for treating or preventing a conditions treatable or preventable by inhibition of a kinase pathway, comprising administering an effective amount of a solid form of any one of claims 1 – 10 to a subject in need thereof.

12. A method for treating or preventing interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus, comprising administering an effective amount of a solid form of any one of claims 1 – 10 to a subject in need thereof


13. A method for treating or preventing liver fibrotic disorders, diabetes, metabolic syndrome leading to liver fibrotic disorders, or a conditions treatable or preventable by inhibition of a kinase pathway, comprising administering an effective amount of a solid form of any one of claims 1 – 10 to a subject in need thereof.

14. A method of preparing a compound of formula (iv),



(iv),

the method comprising contacting a compound of formula (iii),




(iii),

with R^1NH_2 in the presence of a base or a Lewis acid, in a solvent,


wherein R^1 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted saturated cycloalkyl,

wherein R^2 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted cycloalkyl.


15. The method of claim 14, wherein R^2 is



16. The method of claim 14, wherein R^1 is



17. A method of preparing a compound of formula (iii),




(iii),


the method comprising contacting of 2,4-dichloropyrimidine-5-carboxamide with R^2NH_2 in the presence of a base in a solvent,

wherein R^2 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted cycloalkyl.

18. The method of claim 17, wherein R^2 is



19. A method of purifying a compound of formula (iv),




(iv),

the method comprising 1) dissolving the compound of formula (iv) in a first solvent at a first temperature; 2) adding a second solvent into the resulting solution; 3) cooling the solution to a second temperature; and 4) collecting a solid,

wherein R^1 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted cycloalkyl;

and R^2 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted cycloalkyl.

20. A compound of formula (iii),




(iii),

and tautomers thereof,

wherein R^2 is substituted or unsubstituted C_{1-8} alkyl, or substituted saturated cycloalkyl.

21. The compound of claim 20, wherein R^2 is




22. The crystal form or solid form of any one of claims 1 - 10, for use in a method for treating or preventing conditions treatable or preventable by inhibition of a kinase pathway, the method comprises administering an effective amount of the crystal form or solid form to a subject in need thereof.

23. The crystal form or solid form of any one of claims 1 - 10, for use in a method for treating or preventing interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus, the method comprises administering an effective amount of the crystal form or solid form to a subject in need thereof.

24. The crystal form or solid form of any one of claims 1 - 10, for use in a method for treating or preventing liver fibrotic disorders, diabetes, metabolic syndrome leading to liver fibrotic disorders, or a conditions treatable or preventable by inhibition of a kinase pathway, the method comprises administering an effective amount of the crystal from or solid form to a subject in need thereof.

What is claimed is:


1. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 10.55, 13.61 and 19.84° 2θ.


2. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.80, 17.29 and 21.74° 2θ.


3. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.83, 17.26 and 21.86° 2θ.


4. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 10.37, 13.41 and 19.52° 2θ.


5. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.92, 17.29 and 21.81° 2θ.


6. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 18.53, 20.85 and 21.10° 2θ.


7. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.51, 17.90 and 21.28° 2θ.


8. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 9.74, 17.22 and 21.76° 2θ.


9. A crystal form comprising Compound 1, or a tautomer thereof:



1

which has an X-ray powder diffraction pattern comprising peaks at approximately 7.94, 16.00 and 18.27° 2θ.

10. An amorphous solid comprising Compound 1, or a tautomer thereof:




1.

11. Use of a solid form of any one of claims 1 – 10 in the manufacture of a medicament for treating or preventing a condition treatable or preventable by inhibition of a kinase pathway.

12. Use of a solid form of any one of claims 1 – 10 in the manufacture of a medicament for treating or preventing interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus.


13. Use of a solid form of any one of claims 1 – 10 in the manufacture of a medicament for treating or preventing liver fibrotic disorders, diabetes, metabolic syndrome leading to liver fibrotic disorders, or a conditions treatable or preventable by inhibition of a kinase pathway.

14. A method of preparing a compound of formula (iv),



(iv),

the method comprising contacting a compound of formula (iii),




(iii),

with R^1NH_2 in the presence of a base or a Lewis acid, in a solvent,


wherein R^1 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted saturated cycloalkyl,

wherein R^2 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted cycloalkyl.


15. The method of claim 14, wherein R^2 is



16. The method of claim 14, wherein R^1 is



17. A method of preparing a compound of formula (iii),




(iii),


the method comprising contacting of 2,4-dichloropyrimidine-5-carboxamide with R^2NH_2 in the presence of a base in a solvent,

wherein R^2 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted cycloalkyl.

18. The method of claim 17, wherein R^2 is



19. A method of purifying a compound of formula (iv),




(iv),

the method comprising 1) dissolving the compound of formula (iv) in a first solvent at a first temperature; 2) adding a second solvent into the resulting solution; 3) cooling the solution to a second temperature; and 4) collecting a solid,

wherein R^1 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted cycloalkyl;

and R^2 is substituted or unsubstituted C_{1-8} alkyl, or substituted or unsubstituted cycloalkyl.

20. A compound of formula (iii),




(iii),

and tautomers thereof,

wherein R^2 is substituted or unsubstituted C_{1-8} alkyl, or substituted saturated cycloalkyl.

21. The compound of claim 20, wherein R^2 is



22. The crystal form or solid form of any one of claims 1 - 10, for use in a method for treating or preventing conditions treatable or preventable by inhibition of a kinase pathway, the method comprises administering an effective amount of the crystal form or solid form to a subject in need thereof.

23. The crystal form or solid form of any one of claims 1 - 10, for use in a method for treating or preventing interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus, the method comprises administering an effective amount of the crystal form or solid form to a subject in need thereof.

24. The crystal form or solid form of any one of claims 1 - 10, for use in a method for treating or preventing liver fibrotic disorders, diabetes, metabolic syndrome leading to liver fibrotic disorders, or a conditions treatable or preventable by inhibition of a kinase pathway, the method comprises administering an effective amount of the crystal from or solid form to a subject in need thereof.